Abstract
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD) is a chronic relapsing-remitting immune disorder that afflicts millions of individuals throughout the world with debilitating symptom impairing performance and quality of life. The chronic nature of IBD means that afflicted individuals need life-long medications and this can lead to drug dependency, loss of response together with medication related adverse side effects as additional morbidity factors. In recent years, the efficacy of anti-tumor necrosis factor (TNF)-α antibodies like infliximab in patients with IBD has validated the role of certain cytokines, notably TNF-α in the immunopathogenesis of both UC and CD. However, a major source of inflammatory cytokines are myeloid lineage leukocytes (granulocytes and monocytes), which in patients with IBD are elevated with activation behavior and prolonged survival time. Therefore, myeloid leukocytes appear to be logical target of therapy in IBD patients. Based on this knowledge, therapeutic leukocytapheresis has been introduced as a non-pharmacologic treatment intervention in patients with active IBD. In early days, centrifugation was applied to deplete the myeloid leukocytes, but this has been replaced by direct hemoperfusion systems, the Adacolumn and the Cellsorba filter column. The Adacolumn is filled with cellulose beads as leukocytapheresis carriers that selectively adsorb myeloid leukocytes together with a significant fraction of platelets. In contrast, the Cellsorba filter removes lymphocytes in addition to myeloid cells. The efficacy rate for leukocytapheresis has been variable, from an 80 % to statistically insignificant level depending on patients’ baseline disease severity and other relevant demographic variable. First episode cases together with steroid naïve patients have responded well, while patient with extensive deep mucosal IBD lesions have not responded. However, leukocytapheresis therapy in IBD holds promise, but the full efficacy of this non-drug strategy warrants additional controlled trials in large cohorts of IBD patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allison MC, Dhillon AP, Lewis WG, Pounder RE, editors. Inflammatory bowel disease. London: Mosby; 1998. p. 9–95.
Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205.
Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–29.
Harris ML, Bayless TM. Dietary antigens as aggravating factors in Crohn’s disease. Dig Dis Sci. 1989;34:1613–4.
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–78.
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606–19.
Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590–605.
Hart AL, Ng SC, Mann E, Al-Hassi HO, Bernardo D, Knight SC. Homing of immune cells: role in homeostasis and intestinal inflammation. Inflamm Bowel Dis. 2010;16(11):1969–77.
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–17.
Molodecky NA, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Alberta Inflammatory Bowel Disease Consortium. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17(8):1792–9.
Wlodarska M, Kostic AD, Xavier RJ. An integrative view of microbiome-host interactions in inflammatory bowel diseases. Cell Host Microbe. 2015;17(5):577–91.
Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest. 2014;124(10):4190–6.
Shanahan F. Crohn’s disease. Lancet. 2002;359:62–9.
Francescone R, Hou V, Grivennikov SI. Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015;21(2):409–18.
Brenner D, Blaser H, Mak TW. Regulation of tumor necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15(6):362–74.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–57.
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627–40.
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–42.
Schreaiber S, Nikolaus S, Hampe J, Hämling J, Koop I, Groessner B, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn’s disease. Lancet. 1999;353:459–61.
Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289–98.
Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.
Limburg P, David M, Ahlquist A, Sandborn WJ. Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831–7.
Roseth AG, Schmidt PN, Fagerhol MK. Correlation between fecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker. Scand J Gastroenterol. 1999;34:50–4.
Ayabe T, Ashida T, Taniguchi M, et al. A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. Intern Med. 1997;36:322–6.
Ayabe T, Ashida T, Kohgo Y. Centrifugal leukocyte apheresis for ulcerative colitis. Ther Apher. 1998;2:125–8.
McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991;86:489–93.
Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:21–33.
Hanai H, Watanabe F, Saniabadi A, Matsushita I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci. 2002;47:2349–53.
Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjarnason I. Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol. 2003;1:28–35.
Saniabadi AR, Hanai H, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48–59.
Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994;35:669–74.
Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn’s disease and ulcerative colitis. Gastroenterology. 1978;74:501–3.
Brannigan AE, O’Connell PR, Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock. 2000;13:361–6.
Morse EE, Carbone PP, Freireich EJ, Bronson W, Kliman A. Repeated leukapheresis of patients with chronic myelocytic leukemia. Transfusion. 1966;6:175–82.
Buckner D, Graw Jr RG, Eisel RJ, Henderson ES, Perry S. Leukapheresis by continuous flow centrifugation CFC; in patients with chronic myelocytic leukemia CML. Blood. 1969;33:353–69.
Curtis JE, Hersh EM, Freireich EJ. Leukoapheresis therapy of chronic lymphocytic leukemia. Blood. 1972;39:163–75.
Pearson CM, Paulus HE, Machleder HI. The role of the lymphocyte and its products in the propagation of joint disease. Ann N Y Acad Sci. 1975;256:150–68.
Tenenbaum J, Urowitz MB, Keystone EC, Dwosh IL, Curtis JE. Leukoapheresis in severe rheumatoid arthritis. Ann Rheum Dis. 1979;38:40–4.
Bicks RO, Groshart KW, Chandler RW. The treatment of severe chronically active Crohn’s disease by T8 suppressor cell; lymphapheresis. Gastroenterology. 1985;88:1325.
Bicks RO, Groshart KW, Chandler RW. The treatment of severe chronically active Crohn’s disease by T lymphocyte apheresis. Gastroenterology. 1986;90:A1346.
Bicks RO, Groshart KW, Luther RW. Total parenteral nutrition TPN; plus T-lymphocyte apheresis TLA; in the treatment of severe chronic active Crohn’s disease. Gastroenterology. 1987;94:A34.
Lerebours E, Bussel A, Modigliani R, et al. Treatment of Crohn’s disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1994;107:357–61.
Kohgo Y, Hibi T, Chiba T, Study group for Alternative Therapies in Ulcerastive Colitis Patients. Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial. Ther Apher. 2002;6:255–60.
Hiraishi K, Takeda Y, Saniabadi A, et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial. 2003;7:334–40.
Saniabadi AR, Hanai H, Suzuki Y, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171–84.
Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol. 1998;10:411–3.
Cuadrado E, Alonso M, De Juan MD, Echaniz P, Arenas JI. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. World J Gastroenterol. 2008;14:1521–7.
Shimoyama T, Sawada K, Saniabadi A. Safety and efficacy of granulocyte and monocyte apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001;16:1–9.
Hanauer SB. Can cyclosporine go it alone in severe ulcerative colitis. Curr Gastroenterol Rep. 2001;3:455–6.
Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv. 2004;4:97–107.
Kanke K, Nakano M, Hiraishi H, Terano A. Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004;36:512–8.
Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251–7.
Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004;20:783–92.
Premchand P, Takeuchi K, Bjarnason I. Granulocyte, macrophage, monocyte apheresis for refractory ulcerative proctitis. Eur J Gastroenterol Hepatol. 2004;16:943–5.
Domenech E, Hinojosa J, Esteve-Comas M, Gassull A, Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347–52.
Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49:565–71.
Cohen RD. Treating ulcerative colitis without medications—“Look Mom, No Drugs!”. Gastroenterology. 2005;128:235–6.
Maiden L, Takeuchi K, Bjarnason I, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis. 2008;14:1413–8.
Sleasman JW. The association between immunodeficiency and the development of autoimmune disease. Adv Dent Res. 1996;10:57–61.
Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn’s disease: a report on seven refractory patients. Am J Gastroenterol. 2003;98:511–2.
Fukuda Y, Matsui T, Suzuki Y, Kanke K, Hibi T. Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol. 2004;39:1158–64.
Muratov V, Lundahl J, Ulfgren AK, et al. Downregulation of interferon-g parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int J Colorectal Dis. 2006;21(6):493–504.
Hanai H, Watanabe F, Saniabadi A, et al. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004;99:1532–8.
Mohler KM, Torrance DS, Smith GA, Widmer MB. Soluble tumor necrosis factor TNF; receptors are effective therapeutic agents in lethal endotoximia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548–61.
Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher. 1998;2:134–41.
Ansary MM, Ishihara S, Oka A, Kusunoki R, Oshima N, Yuki T, et al. Apoptotic cells ameliorate chronic intestinal inflammation by enhancing regulatory B-cell function. Inflamm Bowel Dis. 2014;20:2308–20.
Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, et al. CD19 + CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013;5:173ra23.
Sono K, Yamada A, Yoshimatsu Y, Takada N, Suzuki Y. Factors associated with the loss of response to infliximab in patients with Crohn’s disease. Cytokine. 2012;59:410–6.
Sawada K, Muto T, Shimoyama T, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis colum. Curr Pharm Des. 2003;9:307–21.
Shirokaze J. Leukocytapheresis using a leukocyte removal filter. Ther Apher. 2002;6:261–6.
Sawada K, Ohnishi K, Fukui S. Leukocytapheresis therapy performed with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol. 1995;30:322–9.
Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol. 2005;100:1362–9.
Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kasuka T, Shimoyama T. Leukocytapheresis LCAP; for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci. 2005;50:767–73.
Sawada K, Muto T, Shimoyama T. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher. 1997;1:207–11.
Yamaji K, Yang K, Tsuda H, Hashimoto H. Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther Apher. 2002;6:402–12.
Shibata H, Kuriyama T, Yamawaki N. Cellsorba. Ther Apher Dial. 2003;7:44–7.
King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 2004;117:265–77.
Yoshimura N, Tadami T, Kawaguchi T, et al. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leukocytes. J Gastroenterol. 2012;47:49–55.
Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990–5.
Yamamoto T, Umegae S, Natsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol. 2011;46:1003–9.
Sands BE, Sandborn WJ, Feagan B, Adacolumn Study Group, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400–9.
Sands BE, Katz S, Wolf DC, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn’s disease. Gut. 2013;62:1288–94.
Hibi T, Sameshima Y, Sekiguchi Y, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centers in Japan. Dig Liver Dis. 2009;41:570–7.
Yokoyama Y, Matsuoka K, Kobayashi T, et al. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. J Crohns Colitis. 2014;8:981–91.
Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of appoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996;156:4422–8.
Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today. 1995;16:21–6.
Nikolaus S, Bauditz J, Gionchetti P. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut. 1998;42:470–6.
Noguchi M, Hiwatashi N, Hayakawa T, Toyota T. Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther Apher. 1998;2:109–14.
Andoh A, Tsujikawa T, Inatomi O, et al. Leukocytaoheresis therapy modulates circulating T cell subsets in patients with ulcerative colitis. Ther Apher Dial. 2005;9:270–9.
Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:48–57.
Hanauer SB. Medical therapy of ulcerative colitis. Gastroenterology. 2004;126:1582–92.
Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003;29:185–202.
Bromley SK, Thomas SY, Luster AD. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol. 2005;6:895–901.
Egan LJ, Sandborn WJ. Advances in the treatment of Crohn’s disease. Gastroenterology. 2004;126:1574–81.
Shand A, Forbes A. Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn’s disease: in the shadow of infliximab? Int J Colorectal Dis. 2003;18:1–11.
Campbell DJ, Debes GF, Johnston B, Wilson E, Butcher EC. Targeting T cell responses by selective chemokine receptor expression. Semin Immunol. 2003;15:277–86.
Mackay CR, Marston WL, Dudler L. Naïve and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med. 1990;171:801–17.
Olszewski WL. The lymphatic system in body homeostasis: physiological conditions. Lymphat Res Biol. 2003;1:11–21.
Debes GF, Arnold CN, Young AJ, et al. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol. 2005;6:889–94.
Klonowski KD. Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity. 2004;20:551–62.
Lee A, Whyte M, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol. 1993;54:283–8.
Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci. 2006;51:2031–8.
Study for the treatment of Crohn’s disease with adacolumn. post-hoc: clinical response in subjects with a CDAI score greater than 300. https://clinicaltrials.gov/ct2/home. Accessed June 2015.
Saniabadi AR, Tanaka T, Ohmori T, et al. Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol. 2014;20:9699–715.
Hanai H, Takeuchi K, Iida T, et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci. 2004;49:1438–43.
Tanaka T, Okanobu H, Yoshimi S, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis. 2008;40:731–6.
Yokoyama Y, Kawai M, Fukunaga K, et al. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27.
Yokoyama Y, Watanabe K, Ito H, et al. Factors associated with treatment outcome and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leukocytes: a prospective multicenter study. Cytotherapy. 2015;17:680–8.
Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–75.
Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol. 2014;27:1–7.
Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis. 2012;6:750–5.
Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Aliment Pharmacol Ther. 1997;11:1031–5.
Kruis W, Nguyen GP, Morgenstern J. Granulocyte/monocyte adsorptive apheresis in moderate to severe ulcerative colitis—effective or not? Digestion. 2015;92:39–44.
Takahashi H, Sugawara K, Sugimura M, Iwabuchi M, Mano Y, Ukai K, et al. Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients. Arch Gynecol Obstet. 2013;288:341–7.
Danese S, Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 2014;147(5):981–9.
Bamias G, Clark DJ, Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets. 2013;14:1490–500.
Löwenberg M, D'Haens G. Next-generation therapeutics for IBD. Curr Gastroenterol. 2015;17:444.
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod FTY720 for relapsing multiple sclerosis. N Engl J Med. 2006;14(355):1124–40.
Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, et al. Long-term up to 4.5 years; treatment with fingolimod in multiple sclerosis: results from the extension of the randomized TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2015 June 25. pii: jnnp-2015-310597.
Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, Stein JM. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4 + CD25+ regulatory T cells. J Immunol. 2007;178:2458–68.
D’Ovidio V, Meo D, Gozer M, Bazuro ME, Vernia P. Ulcerative colitis and granulocyte-monocyte-apheresis: safety and efficacy of maintenance therapy during pregnancy. J Clin Apher. 2015;30(1):55–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Kanai, T. (2017). Leukocytapheresis Therapy of Inflammatory Bowel Disease. In: Baumgart, D. (eds) Crohn's Disease and Ulcerative Colitis. Springer, Cham. https://doi.org/10.1007/978-3-319-33703-6_49
Download citation
DOI: https://doi.org/10.1007/978-3-319-33703-6_49
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33701-2
Online ISBN: 978-3-319-33703-6
eBook Packages: MedicineMedicine (R0)